[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644037":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":28,"collaborators":32,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":10},{"fullName":5,"class":6},"Public Union \"Kazakhstan Association of Phthisiopulmonologists\"","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"4HPMZ\u002FHPM Cohort (Short DS-TB Regimen)",null,"Patients with drug-susceptible tuberculosis (DS-TB) receiving the 4-month rifapentine-based regimen: 2 months of isoniazid, rifapentine, moxifloxacin, and pyrazinamide (HPMZ) followed by 2 months of isoniazid, rifapentine, and moxifloxacin (HPM), administered under routine programmatic conditions in Kazakhstan.",{"label":13,"type":10,"description":14,"interventionNames":10},"HRZE\u002FHR Cohort (Standard DS-TB Regimen)","Patients with drug-susceptible tuberculosis (DS-TB) receiving the standard 6-month regimen: 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) followed by 4 months of isoniazid and rifampicin (HR), administered under routine programmatic conditions in Kazakhstan.",{"label":16,"type":10,"description":17,"interventionNames":10},"1HP Cohort (TB Infection Regimen)","Individuals with tuberculosis infection (TBI) receiving the 1-month regimen of daily isoniazid and rifapentine (1HP) under routine programmatic conditions in Kazakhstan. Includes people living with and without HIV.",[19,24],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Elmira Gurbanova, MD, PhD","CONTACT","+37256144656","elmiragurbanova@gmail.com",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},"Gulnaz Musabekova, MD","+77776814267","gulnazmussabekova@gmail.com",{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Elmira Gurbanova","Principal Investigator",[33],{"name":34,"class":35},"The Western-Eastern European Partnership Initiative on HIV, Viral Hepatitis and TB","UNKNOWN","100644037","rifapentine-based-shorter-regimens-for-tuberculosis-and-tb-infection-in-kazakhstan-100644037",false,"NCT07668479","Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan","Research on Evaluating Rifapentine-Based Shorter Regimens for Tuberculosis and Tuberculosis Infection Among People Living With and Without HIV in Programmatic Settings in Kazakhstan (RIFA-REAL)","RIFA-REAL","Inclusion Criteria:\n\nFOR DS-TB COHORTS (2HPMZ\u002F2HPM and 2HRZE\u002F4HR):\n\n* Age 18 years or older\n* Bacteriologically confirmed drug-susceptible pulmonary tuberculosis\n* Newly diagnosed, not previously treated (or treated less than 1 month)\n* Willing and able to provide written informed consent\n* Residing in one of the four pilot regions of Kazakhstan\n\nFOR TBI COHORT (1HP):\n\n* Age 18 years or older\n* Diagnosed with tuberculosis infection\n* No evidence of active tuberculosis disease\n* Willing and able to provide written informed consent\n* Residing in one of the four pilot regions of Kazakhstan\n\nExclusion Criteria:\n\nFOR DS-TB COHORTS:\n\n* Confirmed or suspected drug-resistant tuberculosis (rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant tuberculosis (MDR-TB))\n* Extrapulmonary tuberculosis as the sole manifestation\n* Pregnancy or breastfeeding at time of enrollment\n* Severe hepatic impairment (alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) \\>3x upper limit of normal)\n* Known hypersensitivity to rifapentine, isoniazid, moxifloxacin, or pyrazinamide\n* corrected QT interval (QTc) interval \\>500 ms on baseline electrocardiogram (ECG)\n* Currently receiving medications with significant interactions contraindicated with study regimens\n\nFOR TBI COHORT:\n\n* Active tuberculosis disease\n* Previous treatment for TB or TBI within the past 2 years\n* Pregnancy at time of enrollment\n* Severe hepatic impairment\n* Known hypersensitivity to rifapentine or isoniazid","ALL","18 Years",{"count":47,"type":48},350,"ESTIMATED","OBSERVATIONAL","RIFA-REAL is a prospective observational longitudinal study evaluating the safety, feasibility, and effectiveness of rifapentine-based shorter treatment regimens for drug-susceptible tuberculosis (DS-TB) and tuberculosis infection (TBI) under routine programmatic conditions in Kazakhstan.\n\nThe study enrolls three cohorts: patients with DS-TB receiving the 4-month isoniazid-rifapentine-moxifloxacin-pyrazinamide regimen (2HPMZ\u002F2HPM), patients with DS-TB receiving the standard 6-month isoniazid-rifampicin-pyrazinamide-ethambutol regimen (2HRZE\u002F4HR), and individuals with TBI receiving the 1-month rifapentine-isoniazid regimen (1HP). Participants include people living with and without HIV.\n\nThe study is conducted across four regions of Kazakhstan and is funded through the Western-Eastern European Partnership Initiative on HIV, Viral Hepatitis and TB (WEEPI) grant. Findings will inform national TB policy and contribute to global evidence on programmatic implementation of rifapentine-based regimens.",[52,53,54],"Tuberculosis","Tuberculosis Infection, Latent","Tuberculosis, Pulmonary, Drug Sensitive",[56,57,58,59,60,61,62,63],"rifapentine","4HPMZ","1HP","drug-susceptible tuberculosis","TB infection","shorter treatment regimen","operational research","HIV","NOT_YET_RECRUITING","2026-06-21",{"date":67,"type":68},"2026-06-25","ACTUAL",{"date":70,"type":48},"2026-07-01",{"date":72,"type":48},"2027-08",{"name":5,"class":6}]